These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12465553)

  • 41. Gene therapy depends on finding the right vector.
    Holzman D
    J Natl Cancer Inst; 1995 Mar; 87(6):406-10. PubMed ID: 7861457
    [No Abstract]   [Full Text] [Related]  

  • 42. Toward cystic fibrosis gene therapy.
    Wagner JA; Gardner P
    Annu Rev Med; 1997; 48():203-16. PubMed ID: 9046956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.
    Aitken ML; Moss RB; Waltz DA; Dovey ME; Tonelli MR; McNamara SC; Gibson RL; Ramsey BW; Carter BJ; Reynolds TC
    Hum Gene Ther; 2001 Oct; 12(15):1907-16. PubMed ID: 11589832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease.
    Dunbar CE
    Annu Rev Med; 1996; 47():11-20. PubMed ID: 8712765
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis.
    Wagner JA; Moran ML; Messner AH; Daifuku R; Conrad CK; Reynolds T; Guggino WB; Moss RB; Carter BJ; Wine JJ; Flotte TR; Gardner P
    Hum Gene Ther; 1998 Apr; 9(6):889-909. PubMed ID: 9581911
    [No Abstract]   [Full Text] [Related]  

  • 46. Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis.
    Crystal RG; Mastrangeli A; Sanders A; Cooke J; King T; Gilbert F; Henschke C; Pascal W; Herena J; Harvey BG
    Hum Gene Ther; 1995 May; 6(5):667-703. PubMed ID: 7578402
    [No Abstract]   [Full Text] [Related]  

  • 47. Biological principles and clinical development of prostate cancer gene therapy.
    Sanda MG
    Semin Urol Oncol; 1997 Feb; 15(1):43-55. PubMed ID: 9050139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The potential for gene therapy in the treatment of autoimmune disease.
    Tarner IH; Fathman CG
    Clin Immunol; 2002 Sep; 104(3):204-16. PubMed ID: 12217329
    [No Abstract]   [Full Text] [Related]  

  • 49. Utility of the nasal model in gene transfer studies in cystic fibrosis.
    Graham SM; Launspach JL
    Rhinology; 1997 Dec; 35(4):149-53. PubMed ID: 9532632
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis.
    Zuckerman JB; Robinson CB; McCoy KS; Shell R; Sferra TJ; Chirmule N; Magosin SA; Propert KJ; Brown-Parr EC; Hughes JV; Tazelaar J; Baker C; Goldman MJ; Wilson JM
    Hum Gene Ther; 1999 Dec; 10(18):2973-85. PubMed ID: 10609658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene therapy strategies for pulmonary disease.
    Crystal RG
    Am J Med; 1992 Jun; 92(6A):44S-52S. PubMed ID: 1621744
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Prospects of gene therapy in mucoviscidosis using viral infection of the airway epithelium].
    Bayle JY; Boucher RC
    Rev Mal Respir; 1994; 11(4):345-55. PubMed ID: 7526426
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene therapy prospects--intranasal delivery of therapeutic genes.
    Podolska K; Stachurska A; Hajdukiewicz K; Małecki M
    Adv Clin Exp Med; 2012; 21(4):525-34. PubMed ID: 23240459
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector.
    Hay JG; McElvaney NG; Herena J; Crystal RG
    Hum Gene Ther; 1995 Nov; 6(11):1487-96. PubMed ID: 8573621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recent advances, prospects and problems in designing new strategies for oligonucleotide and gene delivery in therapy.
    Romano G; Claudio PP; Kaiser HE; Giordano A
    In Vivo; 1998; 12(1):59-67. PubMed ID: 9575427
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Problems of gene transfer to human airway in the patients with respiratory diseases].
    Ohwada A
    Nihon Rinsho; 1996 Feb; 54(2):329-33. PubMed ID: 8838077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Primary T lymphocytes as targets for gene therapy.
    Hanazono Y; Brown KE; Dunbar CE
    J Hematother Stem Cell Res; 2000 Oct; 9(5):611-20. PubMed ID: 11091484
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gene targeting with viral vectors.
    Hendrie PC; Russell DW
    Mol Ther; 2005 Jul; 12(1):9-17. PubMed ID: 15932801
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gene therapy for inherited disorders.
    Pickler RH; Munro CL
    J Pediatr Nurs; 1995 Feb; 10(1):40-7. PubMed ID: 7891261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adenovirus-mediated gene transfer for cystic fibrosis: Part A. Safety of dose and repeat administration in the nasal epithelium. Part B. Clinical efficacy in the maxillary sinus.
    Welsh MJ; Zabner J; Graham SM; Smith AE; Moscicki R; Wadsworth S
    Hum Gene Ther; 1995 Feb; 6(2):205-18. PubMed ID: 7537540
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.